Zkusit zdarma
Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.

FHTX
Cena:
$ 4.22
+0.06 (1.44%)
Valuace
100
Růst
60
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

7:00 12-05-2026

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli...

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

9:56 07-05-2026

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks ...

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

7:00 07-05-2026

- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti...

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

11:01 06-05-2026

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a l...

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

16:05 21-04-2026

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY...

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

7:00 09-04-2026

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities i...

Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)

Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)

2:29 29-03-2026

Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get...

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

18:55 11-03-2026

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks ...

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

16:09 11-03-2026

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant ca...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

4:26 11-03-2026

Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus ...

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

7:00 24-02-2026

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cl...

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

7:00 23-02-2026

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cl...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages

3:24 14-02-2026

Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus ratin...

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

7:00 03-02-2026

WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cl...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages

6:13 20-01-2026

Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) has earned an average recommendation of "...

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

16:05 13-01-2026

WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cl...

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

22:20 09-01-2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pion...

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

11:40 18-12-2025

J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in can...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts

1:27 01-12-2025

Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus recom...

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?

10:57 19-11-2025

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the...

close

FOGHORN THERAPEUTICS TO PARTICIPATE IN THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT

03-02-2026
WATERTOWN, MASS., FEB. 03, 2026 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS ANNOUNCES CLOSING OF $50 MILLION REGISTERED DIRECT FINANCING AT A 30% PREMIUM

13-01-2026
WATERTOWN, MASS., JAN. 13, 2026 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS HIGHLIGHTS JANUARY EQUITY FINANCING, PROGRAM PROGRESS AND STRATEGIC OBJECTIVES FOR 2026

09-01-2026
RECENTLY RAISED $50 MILLION WITH BVF PARTNERS, DEERFIELD MANAGEMENT, FOUNDING INVESTOR FLAGSHIP PION...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

25-11-2025
CAMBRIDGE, MASS., NOV. 25, 2025 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS PROVIDES THIRD QUARTER 2025 FINANCIAL AND CORPORATE UPDATE

05-11-2025
ONGOING FHD-909 (LY4050784) PHASE 1 DOSE ESCALATION TRIAL IN SMARCA4 (BRG1)-MUTATED CANCER REMAINS O...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES

03-11-2025
CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS ANNOUNCES UPDATES FOR SELECTIVE ARID1B, SELECTIVE CBP AND SELECTIVE EP300 DEGRADER PROGRAMS

30-10-2025
- DATA PRESENTED AT THE TPD AND INDUCED PROXIMITY SUMMIT DEMONSTRATE THAT NOVEL SELECTIVE ARID1B DEG...
Více zde

FOGHORN THERAPEUTICS ANNOUNCES SIGNIFICANT PROGRESS FOR SELECTIVE ARID1B DEGRADER AT THE 8TH ANNUAL TPD AND INDUCED PROXIMITY SUMMIT

16-10-2025
FOGHORN TO HOST A VIRTUAL INVESTOR EVENT ON UPDATES FOR ITS SELECTIVE ARID1B, SELECTIVE CBP AND SELE...
Více zde

IQVIA AND FLAGSHIP PIONEERING ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH LIFE SCIENCES COMPANIES

28-08-2025
RESEARCH TRIANGLE PARK, N.C. AND CAMBRIDGE, MASS....
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES

27-08-2025
CAMBRIDGE, MASS., AUG. 27, 2025 (GLOBE NEWSWIRE) -- AUGUST 27, 2025 -- FOGHORN® THERAPEUTICS INC. (...
Více zde

FOGHORN THERAPEUTICS PROVIDES SECOND QUARTER 2025 FINANCIAL AND CORPORATE UPDATE

05-08-2025
FHD-909 (LY4050784) PHASE 1 DOSE ESCALATION TRIAL IN SMARCA4 (BRG1) MUTATED CANCERS, WITH NON-SMALL ...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN FOUR UPCOMING INVESTOR CONFERENCES

22-05-2025
CAMBRIDGE, MASS., MAY 22, 2025 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CLI...
Více zde

FOGHORN THERAPEUTICS PROVIDES FIRST QUARTER 2025 FINANCIAL AND CORPORATE UPDATE

14-05-2025
FHD-909 (LY4050784) ADVANCING IN PHASE 1 DOSE ESCALATION TRIAL IN SMARCA4 (BRG1) MUTATED CANCERS, WI...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN THE CITIZENS LIFE SCIENCES CONFERENCE

05-05-2025
CAMBRIDGE, MASS., MAY 05, 2025 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CLI...
Více zde

FOGHORN THERAPEUTICS APPOINTS NEIL GALLAGHER AND STUART DUTY TO ITS BOARD OF DIRECTORS

01-05-2025
CAMBRIDGE, MASS., MAY 01, 2025 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CLI...
Více zde

FOGHORN THERAPEUTICS PRESENTS NEW PRECLINICAL DATA ON SELECTIVE SMARCA2 INHIBITOR FHD-909 AND SELECTIVE CBP AND SELECTIVE EP300 DEGRADER PROGRAMS AND PROVIDES PIPELINE UPDATE

28-04-2025
- FHD-909 (LY4050784) ADVANCING IN PHASE 1 TRIAL IN SMARCA4 (BRG1) MUTATED CANCERS, WITH NON-SMALL C...
Více zde

FOGHORN THERAPEUTICS TO HOST VIRTUAL INVESTOR EVENT TO REVIEW PIPELINE UPDATES IN CONJUNCTION WITH 2025 AACR ANNUAL MEETING

15-04-2025
COMPANY TO SHARE NEW PRECLINICAL COMBINATION DATA FOR FHD-909 (LY4050784), A POTENTIAL FIRST-IN-CLAS...
Více zde

FOGHORN THERAPEUTICS ANNOUNCES NEW PRECLINICAL DATA FOR SELECTIVE SMARCA2 INHIBITOR FHD-909 AND SELECTIVE CBP AND EP300 DEGRADER PROGRAMS AT 2025 AACR MEETING

25-03-2025
- FHD-909 (LY4050784) ADVANCING IN AN ONGOING PHASE 1 TRIAL IN SMARCA4 (BRG1) MUTATED CANCERS, WITH ...
Více zde

FOGHORN THERAPEUTICS PROVIDES FINANCIAL UPDATE FOR 2024 AND 2025 STRATEGIC OUTLOOK

06-03-2025
FIRST-IN-CLASS ORAL SELECTIVE SMARCA2 (BRM) INHIBITOR FHD-909 (LY4050784) CONTINUES ENROLLMENT IN PH...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

25-02-2025
CAMBRIDGE, MASS., FEB. 25, 2025 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS PROVIDES UPDATE ON FHD-286 CLINICAL DEVELOPMENT PROGRAM AND STRATEGIC PRIORITIES

16-12-2024
OBJECTIVE CLINICAL RESPONSES BY STANDARD RESPONSE CRITERIA OBSERVED IN PHASE 1 DOSE ESCALATION TRIAL...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES

12-11-2024
CAMBRIDGE, MASS., NOV. 12, 2024 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS PROVIDES THIRD QUARTER 2024 FINANCIAL AND CORPORATE UPDATE

04-11-2024
FIRST PATIENT DOSED WITH FIRST-IN-CLASS SMARCA2(BRM) SELECTIVE INHIBITOR FHD-909 (LY4050784) IN PHAS...
Více zde

FOGHORN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH FIRST-IN-CLASS ORAL SMARCA2 SELECTIVE INHIBITOR FHD-909 IN A PHASE 1 TRIAL FOR SMARCA4 MUTATED SOLID TUMORS

10-10-2024
PRIMARY TARGET PATIENT POPULATION FOR THE FHD-909 PHASE 1 TRIAL IS  NON-SMALL CELL LUNG CANCER (NSC...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN THE BMO ONCOLOGY SUMMIT

01-10-2024
CAMBRIDGE, MASS., OCT. 01, 2024 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF ANNA RIVKIN, PH.D. AS CHIEF BUSINESS OFFICER

03-09-2024
CAMBRIDGE, MASS., SEPT. 03, 2024 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A C...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES IN SEPTEMBER

28-08-2024
CAMBRIDGE, MASS., AUG. 28, 2024 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CL...
Více zde

FOGHORN THERAPEUTICS PROVIDES SECOND QUARTER 2024 FINANCIAL AND CORPORATE UPDATE

08-08-2024
TOPLINE PHASE 1 DOSE ESCALATION DATA FOR FHD-286 IN COMBINATION WITH DECITABINE, IN RELAPSED AND/OR ...
Více zde

FOGHORN THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNE

28-05-2024
CAMBRIDGE, MASS., MAY 28, 2024 (GLOBE NEWSWIRE) -- FOGHORN® THERAPEUTICS INC. (NASDAQ: FHTX), A CLI...
Více zde

FOGHORN THERAPEUTICS RAISES APPROXIMATELY $110 MILLION THROUGH REGISTERED DIRECT OFFERING TO ADVANCE PIPELINE

22-05-2024
POSITIONS COMPANY TO FURTHER LEVERAGE STRENGTH OF PLATFORM AND ADVANCE PROGRAMS THROUGH MULTIPLE DAT...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-12 00:00:008-KStáhnout
2025-12-04 00:00:008-KStáhnout
2025-11-07 00:00:008-KStáhnout
2025-11-05 00:00:008-KStáhnout
2025-11-05 00:00:0010-QStáhnout
2025-10-30 00:00:008-KStáhnout
2025-09-02 01:00:008-KStáhnout
2025-09-02 00:00:008-KStáhnout
2025-08-05 01:00:008-KStáhnout
2025-08-05 01:00:0010-QStáhnout
2025-08-05 00:00:008-KStáhnout
2025-08-05 00:00:0010-QStáhnout
2025-07-01 01:00:008-KStáhnout
2025-07-01 00:00:008-KStáhnout
2025-06-17 01:00:008-KStáhnout
2025-06-17 00:00:008-KStáhnout
2025-05-14 01:00:008-KStáhnout
2025-05-14 01:00:0010-QStáhnout
2025-05-14 00:00:008-KStáhnout
2025-05-14 00:00:0010-QStáhnout
2025-05-01 01:00:008-KStáhnout
2025-05-01 00:00:008-KStáhnout
2025-04-28 01:00:008-KStáhnout
2025-04-28 00:00:008-KStáhnout
2025-03-24 00:00:008-KStáhnout
2025-03-23 23:00:008-KStáhnout
2025-03-20 00:00:008-KStáhnout
2025-03-19 23:00:008-KStáhnout
2025-03-06 00:00:008-KStáhnout
2025-03-06 00:00:0010-KStáhnout
2025-03-05 23:00:008-KStáhnout
2025-03-05 23:00:0010-KStáhnout
2025-02-03 00:00:008-KStáhnout
2025-02-02 23:00:008-KStáhnout
2025-01-24 00:00:008-KStáhnout
2025-01-23 23:00:008-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-12-30 00:00:008-KStáhnout
2024-12-29 23:00:008-KStáhnout
2024-12-16 00:00:008-KStáhnout
2024-12-15 23:00:008-KStáhnout
2024-11-04 00:00:008-KStáhnout
2024-11-04 00:00:0010-QStáhnout
2024-11-03 23:00:008-KStáhnout
2024-11-03 23:00:0010-QStáhnout
2024-10-10 01:00:008-KStáhnout
2024-10-10 00:00:008-KStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 01:00:0010-QStáhnout
2024-08-08 00:00:008-KStáhnout
2024-08-08 00:00:0010-QStáhnout
2024-06-26 01:00:008-KStáhnout
2024-06-26 00:00:008-KStáhnout
2024-06-03 01:00:008-KStáhnout
2024-06-03 00:00:008-KStáhnout
2024-05-23 01:00:008-KStáhnout
2024-05-23 00:00:008-KStáhnout
2024-05-22 01:00:008-KStáhnout
2024-05-22 00:00:008-KStáhnout
2024-05-20 01:00:008-KStáhnout
2024-05-20 00:00:008-KStáhnout
2024-05-06 01:00:008-KStáhnout
2024-05-06 01:00:0010-QStáhnout
2024-05-06 00:00:008-KStáhnout
2024-05-06 00:00:0010-QStáhnout
2024-04-16 01:00:008-KStáhnout
2024-04-16 00:00:008-KStáhnout
2024-04-09 01:00:008-KStáhnout
2024-04-09 00:00:008-KStáhnout
2024-03-07 00:00:008-KStáhnout
2024-03-07 00:00:0010-KStáhnout
2024-03-06 23:00:008-KStáhnout
2024-03-06 23:00:0010-KStáhnout
2024-02-08 00:00:008-KStáhnout
2024-02-07 23:00:008-KStáhnout
2024-01-17 00:00:008-KStáhnout
2024-01-16 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2024-01-03 00:00:008-KStáhnout
2024-01-02 23:00:008-KStáhnout
2023-11-02 00:00:008-KStáhnout
2023-11-02 00:00:0010-QStáhnout
2023-11-01 23:00:008-KStáhnout
2023-11-01 23:00:0010-QStáhnout
2023-09-08 01:00:008-KStáhnout
2023-09-08 00:00:008-KStáhnout
2023-08-31 01:00:008-KStáhnout
2023-08-31 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-04 01:00:008-KStáhnout
2023-08-04 01:00:0010-QStáhnout
2023-08-04 00:00:008-KStáhnout
2023-08-04 00:00:0010-QStáhnout
2023-06-28 01:00:008-KStáhnout
2023-06-28 00:00:008-KStáhnout
2023-06-22 01:00:008-KStáhnout
2023-06-22 00:00:008-KStáhnout
2023-06-05 01:00:008-KStáhnout
2023-06-05 00:00:008-KStáhnout
2023-05-08 01:00:008-KStáhnout
2023-05-08 01:00:0010-QStáhnout
2023-05-08 00:00:008-KStáhnout
2023-05-08 00:00:0010-QStáhnout
2023-04-24 01:00:008-KStáhnout
2023-04-24 00:00:008-KStáhnout
2023-03-09 00:00:008-KStáhnout
2023-03-09 00:00:0010-KStáhnout
2023-03-08 23:00:008-KStáhnout
2023-03-08 23:00:0010-KStáhnout
2023-03-08 00:00:008-KStáhnout
2023-03-07 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-08 00:00:008-KStáhnout
2022-11-08 00:00:0010-QStáhnout
2022-11-07 23:00:008-KStáhnout
2022-11-07 23:00:0010-QStáhnout
2022-10-27 01:00:008-KStáhnout
2022-10-27 00:00:008-KStáhnout
2022-10-26 01:00:008-KStáhnout
2022-10-26 00:00:008-KStáhnout
2022-08-31 01:00:008-KStáhnout
2022-08-31 00:00:008-KStáhnout
2022-08-23 01:00:008-KStáhnout
2022-08-23 00:00:008-KStáhnout
2022-08-17 01:00:008-KStáhnout
2022-08-17 00:00:008-KStáhnout
2022-08-09 01:00:008-KStáhnout
2022-08-09 01:00:0010-QStáhnout
2022-08-09 00:00:008-KStáhnout
2022-08-09 00:00:0010-QStáhnout
2022-06-23 01:00:008-KStáhnout
2022-06-23 00:00:008-KStáhnout
2022-06-08 01:00:008-KStáhnout
2022-06-08 00:00:008-KStáhnout
2022-05-19 01:00:008-KStáhnout
2022-05-19 00:00:008-KStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 01:00:0010-QStáhnout
2022-05-09 00:00:008-KStáhnout
2022-05-09 00:00:0010-QStáhnout
2022-04-15 01:00:008-KStáhnout
2022-04-15 00:00:008-KStáhnout
2022-03-10 00:00:008-KStáhnout
2022-03-10 00:00:0010-KStáhnout
2022-03-09 23:00:008-KStáhnout
2022-03-09 23:00:0010-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-12-21 00:00:008-KStáhnout
2021-12-20 23:00:008-KStáhnout
2021-12-13 00:00:008-KStáhnout
2021-12-12 23:00:008-KStáhnout
2021-11-09 00:00:008-KStáhnout
2021-11-09 00:00:0010-QStáhnout
2021-11-08 23:00:008-KStáhnout
2021-11-08 23:00:0010-QStáhnout
2021-09-01 01:00:008-KStáhnout
2021-09-01 00:00:008-KStáhnout
2021-08-23 01:00:008-KStáhnout
2021-08-23 00:00:008-KStáhnout
2021-08-10 01:00:008-KStáhnout
2021-08-10 01:00:0010-QStáhnout
2021-08-10 00:00:008-KStáhnout
2021-08-10 00:00:0010-QStáhnout
2021-07-14 01:00:008-KStáhnout
2021-07-14 00:00:008-KStáhnout
2021-07-09 01:00:008-KStáhnout
2021-07-09 00:00:008-KStáhnout
2021-06-15 01:00:008-KStáhnout
2021-06-15 00:00:008-KStáhnout
2021-06-01 01:00:008-KStáhnout
2021-06-01 00:00:008-KStáhnout
2021-05-11 01:00:0010-QStáhnout
2021-05-11 00:00:0010-QStáhnout
2021-04-28 01:00:008-KStáhnout
2021-04-28 00:00:008-KStáhnout
2021-03-23 00:00:008-KStáhnout
2021-03-22 23:00:008-KStáhnout
2021-03-18 00:00:008-KStáhnout
2021-03-18 00:00:0010-KStáhnout
2021-03-17 23:00:008-KStáhnout
2021-03-17 23:00:0010-KStáhnout
2021-02-16 00:00:008-KStáhnout
2021-02-15 23:00:008-KStáhnout
2020-12-04 00:00:008-KStáhnout
2020-12-04 00:00:0010-QStáhnout
2020-12-03 23:00:008-KStáhnout
2020-12-03 23:00:0010-QStáhnout
2020-11-25 00:00:008-KStáhnout
2020-11-24 23:00:008-KStáhnout
2020-10-27 00:00:008-KStáhnout
2020-10-26 23:00:008-KStáhnout
preloader